List of Vaccinex, Inc patents

Patents where

Current Assignee

Name

‌

Vaccinex, Inc

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7919594 Human anti-CD100 antibodies	Patent 7919594 was granted and assigned to Vaccinex, Inc on April, 2011 by the United States Patent and Trademark Office.		‌ Vaccinex, Inc	United States Patent and Trademark Office	7919594	April 5, 2011
‌ US Patent 10301393 Methods of treating multiple sclerosis using anti-CD20 antibodies	Patent 10301393 was granted and assigned to Vaccinex, Inc on May, 2019 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10301393	May 28, 2019
‌ US Patent 9243068 Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases	Patent 9243068 was granted and assigned to Vaccinex, Inc on January, 2016 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9243068	January 26, 2016
‌ US Patent 9828435 Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency	Patent 9828435 was granted and assigned to Vaccinex, Inc on November, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9828435	November 28, 2017
‌ US Patent 11078295 Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases	Patent 11078295 was granted and assigned to Vaccinex, Inc on August, 2021 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	11078295	August 3, 2021
‌ US Patent 11427634 Human anti-semaphorin 4D antibody	Patent 11427634 was granted and assigned to Vaccinex, Inc on August, 2022 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	11427634	August 30, 2022
‌ US Patent 11534488 Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability	Patent 11534488 was granted and assigned to Vaccinex, Inc on December, 2022 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	11534488	December 27, 2022
‌ US Patent 11274149 Anti-CD100 antibodies and methods for using the same	Patent 11274149 was granted and assigned to Vaccinex, Inc on March, 2022 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	11274149	March 15, 2022
‌ US Patent 9701958 Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunits	Patent 9701958 was granted and assigned to Vaccinex, Inc on July, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9701958	July 11, 2017
‌ US Patent 9708601 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus	Patent 9708601 was granted and assigned to Vaccinex, Inc on July, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9708601	July 18, 2017
‌ US Patent 10550199 Integral membrane protein display on poxvirus extracellular enveloped virions	Patent 10550199 was granted and assigned to Vaccinex, Inc on February, 2020 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10550199	February 4, 2020
‌ US Patent 9598495 Use of semaphorin-4D binding molecules for treating neurodegenerative disorders	Patent 9598495 was granted and assigned to Vaccinex, Inc on March, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9598495	March 21, 2017
‌ US Patent 9249227 Use of semaphorin-4D binding molecules for treating neurodegenerative disorders	Patent 9249227 was granted and assigned to Vaccinex, Inc on February, 2016 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9249227	February 2, 2016
‌ US Patent 9676840 Anti-CD100 neutralizing antibodies and methods of using the same	Patent 9676840 was granted and assigned to Vaccinex, Inc on June, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9676840	June 13, 2017
‌ US Patent 9809654 Targeted CD1d molecules	Patent 9809654 was granted and assigned to Vaccinex, Inc on November, 2017 by the United States Patent and Trademark Office.		‌ Vaccinex, Inc	United States Patent and Trademark Office	9809654	November 7, 2017
‌ US Patent 9605055 Anti-CD100 antibodies and methods of using the same	Patent 9605055 was granted and assigned to Vaccinex, Inc on March, 2017 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9605055	March 28, 2017
‌ US Patent 9963504 Anti-CXCL13 antibodies and methods of using the same	Patent 9963504 was granted and assigned to Vaccinex, Inc on May, 2018 by the United States Patent and Trademark Office.		‌ Vaccinex, Inc	United States Patent and Trademark Office	9963504	May 8, 2018
‌ US Patent 10662422 Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit		‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10662422	May 26, 2020
‌ US Patent 8496938 Anti-CD100 neutralizing neutralizing antibodies and methods of using the same	Patent 8496938 was granted and assigned to Vaccinex, Inc on July, 2013 by the United States Patent and Trademark Office.		‌ Vaccinex, Inc	United States Patent and Trademark Office	8496938	July 30, 2013
‌ US Patent 10640765 Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells		‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10640765	May 5, 2020
‌ US Patent 9512224 Use of semaphorin-4D binding molecules for treatment of atherosclerosis	Patent 9512224 was granted and assigned to Vaccinex, Inc on December, 2016 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	9512224	December 6, 2016
‌ US Patent 10526414 Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases	Patent 10526414 was granted and assigned to Vaccinex, Inc on January, 2020 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10526414	January 7, 2020
‌ US Patent 10577427 Integral membrane protein display on poxvirus extracellular enveloped virions	Patent 10577427 was granted and assigned to Vaccinex, Inc on March, 2020 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10577427	March 3, 2020
‌ US Patent 10385136 Use of semaphorin-4D binding molecules for treating neurodegenerative disorders	Patent 10385136 was granted and assigned to Vaccinex, Inc on August, 2019 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	10385136	August 20, 2019
‌ US Patent 8790652 Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis	Patent 8790652 was granted and assigned to Vaccinex, Inc on July, 2014 by the United States Patent and Trademark Office.	‌ Vaccinex, Inc	‌ Vaccinex, Inc	United States Patent and Trademark Office	8790652	July 29, 2014

Results per page:

46 results

0 selected

46 results

0 selected